Acenosol

# Acenosol ## Overview - **Classification**: Novel broad-spectrum synthetic antibacterial. - **Mechanism**: Inhibits bacterial protein synthesis by binding reversibly to the 50S ribosomal subunit, preventing peptide bond formation. Bacteriostatic, but may be bactericidal at higher concentrations. ## Primary Indications 1. **Complicated Skin and Soft Tissue Infections (cSSTI)** - Infections requiring systemic therapy, including abscesses, cellulitis, and wound infections. 2. **Community-Acquired Pneumonia (CAP)** - Mild to severe CAP caused by susceptible organisms. 3. **Complicated Urinary Tract Infections (cUTI)** - Including pyelonephritis, caused by susceptible Gram-negative bacteria. ## Adult Dosing ### Standard Dosing **Complicated Skin and Soft Tissue Infections (cSSTI)** - **Dose**: **500 mg** - **Frequency**: Every 12 hours - **Route**: Oral (PO) or Intravenous (IV) - **Duration**: 7 to 14 days **Community-Acquired Pneumonia (CAP)** - **Dose**: **750 mg** - **Frequency**: Every 24 hours - **Route**: Oral (PO) or Intravenous (IV) - **Duration**: 5 to 10 days **Complicated Urinary Tract Infections (cUTI)** - **Dose**: **250 mg** - **Frequency**: Every 12 hours - **Route**: Oral (PO) or Intravenous (IV) - **Duration**: 7 to 10 days ### Dose Adjustments - **Renal Impairment**: - CrCl 30-60 mL/min: Reduce dose by 25% for q12h regimens. No adjustment for **750 mg** q24h. - CrCl <30 mL/min: Reduce dose by 50% or extend interval for q12h regimens. No adjustment for **750 mg** q24h. - Hemodialysis: Administer dose after dialysis. - **Hepatic Impairment**: - Mild-moderate (Child-Pugh A/B): No dose adjustment needed. - Severe (Child-Pugh C): Use with caution; consider dose reduction and close monitoring. - **Elderly Patients**: Monitor renal function closely. No specific dose adjustment solely based on age. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: **5 mg/kg** - **Frequency**: Every 24 hours - **Route**: Intravenous (IV) - **Maximum**: **50 mg/dose** - **Special Notes**: Use only if no suitable alternatives exist due to limited safety data. Close monitoring for adverse effects is crucial. ### Infants (1-12 months) - **Dose**: **10 mg/kg** - **Frequency**: Every 12 hours - **Route**: Oral (PO) or Intravenous (IV) - **Maximum**: **100 mg/dose** - **Special Notes**: Oral suspension may be preferred for ease of administration. ### Children (1-12 years) - **Dose**: **15 mg/kg** - **Frequency**: Every 12 hours - **Route**: Oral (PO) or Intravenous (IV) - **Maximum**: **250 mg/dose** (or adult dose equivalent for specific indications) - **Special Notes**: Ensure accurate weight-based dosing to prevent under or overdosing. ### Adolescents (13-18 years) - **Dose**: Use adult dosing guidelines and indications. - **Maximum**: **500 mg/dose** for q12h regimens, or **750 mg/dose** for q24h regimens. - **Special Notes**: Closely follow adult safety and monitoring parameters. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to Acenosol or any component. - **Absolute**: Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin). - **Absolute**: History of QT prolongation or uncorrected hypokalemia/hypomagnesemia. - **Relative**: Severe uncompensated hepatic impairment. ### Common Adverse Effects - **Very Common (>10%)**: Nausea, Diarrhea, Headache. - **Common (1-10%)**: Vomiting, Abdominal pain, Dizziness, Rash, Photosensitivity. - **Serious but Rare**: QT prolongation (arrhythmias), *Clostridioides difficile*-associated diarrhea (CDAD), Hepatotoxicity, Stevens-Johnson syndrome, Tendonitis/Tendon rupture (especially in elderly). ### Key Drug Interactions - **Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir)**: Markedly increase Acenosol plasma levels, increasing risk of QT prolongation. **Avoid co-administration**. - **QT-prolonging Agents (e.g., Amiodarone, Sotalol)**: Additive risk of QT prolongation and Torsade de Pointes. **Avoid concurrent use**. - **Warfarin**: May enhance anticoagulant effect (increased INR). Monitor INR closely, adjust warfarin dose as needed. - **Antacids (containing Mg/Al) & Iron/Zinc Salts**: May chelate Acenosol, reducing absorption. Separate administration by **2-4 hours**. ## Monitoring & Follow-up - **Before Treatment**: - Baseline Liver Function Tests (LFTs). - Renal function (eGFR or CrCl). - Electrolytes (K+, Mg2+) if risk factors for QT prolongation. - ECG if cardiac risk factors are present. - **During Treatment**: - LFTs weekly if prolonged therapy or hepatic impairment. - Renal function as clinically indicated. - ECG monitoring if co-administered with other QT-prolonging drugs or new cardiac symptoms. - Monitor for signs/symptoms of CDAD (persistent diarrhea). - Assess for rash, photosensitivity, or tendon pain/swelling. - **Clinical Signs**: Watch for persistent diarrhea (CDAD), jaundice (hepatotoxicity), palpitations/syncope (QT prolongation), severe rash (SJS), or joint/tendon pain. ## Clinical Pearls - 💡 Administer oral Acenosol with food to minimize gastrointestinal upset. - 💡 Counsel patients to use sun protection due to potential for photosensitivity. - 💡 Complete the full prescribed course of therapy, even if symptoms improve, to prevent resistance and recurrence. - 💡 Advise patients to report any new onset diarrhea, rash, or tendon pain immediately. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.